Evidence map›Paper›PMID 21975749›Full record

SynthesisThe Cochrane database of systematic reviews2011

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.

Milo A Puhan, Elena Gimeno-Santos, Madlaina Scharplatz, Thierry Troosters, E Haydn Walters, Johann Steurer

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 175 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 21 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02946658 phase1 / phase2suspendednot on this mapstarted 2016, after this paper: background citation

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Chronic Lung Disorders

TypeinterventionalSponsorHealeon Medical IncRan2016 to 2027Enrolled100ConditionsLung DiseaseArmslipoaspiration, ADcSVF, Normal Saline IV
NCT03909750 phase1suspendednot on this mapstarted 2019, after this paper: background citation

Use of Autologous Stem/Stromal Cells in Chronic Lung Disorders: Obstructive (COPD) and Restrictive (RLD)

TypeinterventionalSponsorHealeon Medical IncRan2019 to 2026Enrolled50ConditionsCOPD, Respiratory InsufficiencyArmsLipoaspiration, AD-cSVF, Normal Saline IV
3 · Its place in the literature

Who cites it

175 citing papers in PubMed, 21 syntheses or guidelines pooled it, 380 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Design of pulmonary rehabilitation programmes during acute exacerbations of COPD: a systematic review and network meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.European respiratory review : an official journal of the European Respiratory Society · 2015
    Pooled it
  13. Pooled it
  14. Pulmonary rehabilitation for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2015
    Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Long-acting beta2-agonists for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2013
    Pooled it

115 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 5 countries.

Milo A PuhanEpidemiology, Johns Hopkins Bloomberg School of Public Health, 615 Wolfe Street, Mail room W5010, Baltimore, MD, USA, 21205.
Elena Gimeno-Santos
Madlaina Scharplatz
Thierry Troosters
E Haydn Walters
Johann Steurer
Horten Kommune · NOCenter for Research in Environmental Epidemiology · ESJohns Hopkins University · USKU Leuven · BEUniversity of Tasmania · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary rehabilitation has become a cornerstone in the management of patients with stable Chronic Obstructive Pulmonary Disease (COPD). Systematic reviews have shown large and important clinical effects of pulmonary rehabilitation in these patients. However, in unstable COPD patients who have recently suffered an exacerbation, the effects of pulmonary rehabilitation are less established.

objectivesTo assess the effects of pulmonary rehabilitation after COPD exacerbations on future hospital admissions (primary outcome) and other patient-important outcomes (mortality, health-related quality of life and exercise capacity). SEARCH STRATEGY: Trials were identified from searches of CENTRAL, MEDLINE, EMBASE, PEDRO and the Cochrane Airways Group Register of Trials. Searches were current as of March 2010. SELECTION CRITERIA: Randomized controlled trials comparing pulmonary rehabilitation of any duration after exacerbation of COPD with conventional care. Pulmonary rehabilitation programmes needed to include at least physical exercise. Control groups received conventional community care without rehabilitation. DATA COLLECTION AND ANALYSIS: We calculated pooled odds ratios and weighted mean differences (MD) using random-effects models. We requested missing data from the authors of the primary studies. MAIN

resultsWe identified nine trials involving 432 patients. Pulmonary rehabilitation significantly reduced hospital admissions (pooled odds ratio 0.22 [95% CI 0.08 to 0.58], number needed to treat (NNT) 4 [95% CI 3 to 8], over 25 weeks) and mortality (OR 0.28; 95% CI 0.10 to 0.84), NNT 6 [95% CI 5 to 30] over 107 weeks). Effects of pulmonary rehabilitation on health-related quality of life were well above the minimal important difference when measured by the Chronic Respiratory Questionnaire (MD for dyspnea, fatigue, emotional function and mastery domains between 0.81 (fatigue; 95% CI 0.16 to 1.45) and 0.97 (dyspnea; 95% CI 0.35 to 1.58)) and the St. Georges Respiratory Questionnaire total score (MD -9.88; 95% CI -14.40 to -5.37); impacts domain (MD -13.94; 95% CI -20.37 to -7.51) and for activity limitation domain (MD -9.94; 95% CI -15.98 to -3.89)). The symptoms domain of the St. Georges Respiratory Questionnaire showed no significant improvement. Pulmonary rehabilitation significantly improved exercise capacity and the improvement was above the minimally important difference (six-minute walk test (MD 77.70 meters; 95% CI 12.21 to 143.20) and shuttle walk test (MD 64.35; 95% CI 41.28 to 87.43)). No adverse events were reported in three studies. AUTHORS'

conclusionsEvidence from nine small studies of moderate methodological quality, suggests that pulmonary rehabilitation is a highly effective and safe intervention to reduce hospital admissions and mortality and to improve health-related quality of life in COPD patients who have recently suffered an exacerbation of COPD.

Indexed as

Exercise ToleranceDisease ProgressionHealth StatusHospitalizationHumansPulmonary Disease, Chronic ObstructiveQuality of LifeRandomized Controlled Trials as TopicResistance Training

Identifiers

PMID21975749
OpenAlexW4252718630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.